FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL								
OMB Number:	3235-0287							
Estimated average burd	en							
hours per response:	0.5							

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person* GILMAN STEVEN C					2. Issuer Name and Ticker or Trading Symbol Akebia Therapeutics, Inc. [AKBA]									5. Relationship of Reporting Person(s) to Issuer (Check all applicable)					
OILIVII	III	<u> LIV C</u>												X	Director			10% Ov	
(Last) (First) (Middle)						3. Date of Earliest Transaction (Month/Day/Year) 06/06/2019									Officer (below)	give title		Other (s below)	specify
C/O AKEBIA THERAPEUTICS, INC.						30/2	013												
245 FIRST ST.					4. If Amendment, Date of Original Filed (Month/Day/Year)									6. Individual or Joint/Group Filing (Check Applicable Line)					
(Street)													- [X	Form fil	ed by One	Dono	rting Persor	,
CAMBR	IDGE M	ſΑ	02142											Λ		,		One Repor	
(City)	(\$	State)	(Zip)																
		Та	ble I - Nor	n-Deriv	ative	Se	curities	Acq	uired,	Dis	oosed of	, or Be	nefici	ally	Owned				
1. Title of Security (Instr. 3) 2. Transar Date (Month/Da					Day/Year)		2A. Deemed Execution Date, if any (Month/Day/Year)		Transaction Disposed Code (Instr.			ties Acquired (A) o I Of (D) (Instr. 3, 4		Securitie Beneficia Owned F		es Fo ally (D) Following (I)		: Direct Indirect str. 4)	7. Nature of Indirect Beneficial Ownership
									Code	v	Amount (A) or (D)		r Pric	ce	Reported Transaction(s) (Instr. 3 and 4)				(Instr. 4)
Common Stock 06/0					5/2019		A		13,700 ⁽¹⁾ A		\$(0.00	23,931			D			
			Table II -								osed of, onvertib				wned				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution D if any (Month/Day/	ate, Tra	Transaction Code (Instr.		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)			8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)	
													Amo	unt		Transacti (Instr. 4)	on(s)		
				Co	ode V	,	(A)	(D)	Date Exercisa		Expiration Date	Title	Num of Shar	.					
Stock Option (Right to	\$4.23	06/06/2019		1	A		20,100 ⁽²⁾		06/06/20	20	06/06/2029	Common Stock	20,1	100	\$0.00	20,10	0	D	

Explanation of Responses:

Remarks:

/s/ Nicole R. Hadas, attorney-infact for Steven C. Gilman 06/10/2019

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

^{1.} The restricted stock units were granted by the Issuer pursuant to its 2014 Incentive Plan, as amended, as provided by the Issuer's Amended and Restated Non-Employee Director Compensation Program (the "RSUs"). 100% of the RSUs will vest on the first anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer.

^{2.} Represents an option to purchase shares of the Issuer's common stock granted by the Issuer pursuant to its 2014 Incentive Plan, as amended, as provided by the Issuer's Amended and Restated Non-Employee Director Compensation Program (the "Stock Option"). 100% of the Stock Option will vest and become exercisable on the first anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer.